Leo International Precision Health AG builds a Synchronised, End-to-End Precision Healthcare Engine Across the Entire Patient Journey

LIPH AG introduces a synchronised “Precision Health Engine” designed to transform healthcare from reactive treatment into predictive, personalised and continuous care.

Planegg / Martinsried, Germany, May 26, 2026 – Leo International Precision Health AG (“LIPH AG” or the “Company”, ticker symbol: LEOW), a holding company building a global AI-driven healthcare ecosystem and listed on the Frankfurt Stock Exchange, continues to expand its precision health platform integrating Healthcare Services, MedTech, HealthTech and Biotech into one synchronised ecosystem

Following its transformational 2025 fiscal year, including its listing on the General Standard of the Frankfurt Stock Exchange and the acquisition of six majority stakes in December 2025, the Company has established the operating foundation for a complementary platform in which data, technology and clinical expertise are increasingly interconnected.

"The next chapter of healthcare will not be written by isolated assets, but by intelligent ecosystems. Our six strategic asset companies give LIPH AG a distinctive foundation across AI, diagnostics, clinical access, rehabilitation, recovery support and longevity science. The value lies not only in what each company can achieve individually, but in how they can reinforce one another to create a more integrated, scalable and patient-centred healthcare platform. We are not building standalone companies independently. Instead, we are building an integrated ecosystem where each company strengthens the others, unlocking synergies and amplifying value creation across the entire portfolio,” said Leo Wang, Chairman of the Supervisory Board of LIPH AG.

LIPH AG’s ecosystem brings together six strategic portfolio companies acquired in December 2025 across AI healthcare, precision diagnostics, molecular pathology, functional supplements, preventive wellness and longevity science. Beyond their individual value, competitive strengths and growth potential, these assets are strategically positioned as complementary building blocks within an integrated precision healthcare ecosystem designed to generate cross-platform synergies, long-term value creation and scalable healthcare integration.

These assets include:

amiko AI – AI-Powered Biomedical Intelligence

Headquartered in Taiwan, amiko AI is developing an “AI Co-Scientist” platform focused on biomedical reasoning, ontology-driven AI systems and AI-assisted drug discovery. Its technologies are designed to accelerate scientific discovery, precision diagnostics and AI-driven healthcare orchestration.

Schreibe Deinen Kommentar